UniQure NV of the Netherlands has appointed Dan Soland as its new chief executive, succeeding Jörn Aldag who is stepping down after six years in the post. Mr Aldag led the company when it received marketing authorisation for Glybera, the western world’s first gene therapy. Mr Soland was previously chief operating officer at ViroPharma, a rare disease drug producer that was acquired by Shire Plc in 2014. He has also been president of Chiron Vaccines, CEO of Epigenesis Pharmaceuticals and director of marketing at GlaxoSmithKline Biologicals.
UniQure announced the appointment on 18 December 2015.
Copyright 2015 Evernow Publishing Ltd